Knowthestock.com
ADPT - Adaptive Biotechnologies Corp

Sell

Weak GrowthEarnings/Profit is Negative
WeakStrong
WeakStrong

28%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 8.61%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -74.84%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 2.92
Debt Ratio is 0.63
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.26
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Adaptive Biotechnologies Corp (ADPT) - https://www.adaptivebiotech.com
we are a commercial-stage, biotechnology organization located in the hot biotech locations of seattle, washington and south san francisco, ca. our world class scientists have invented a patent-pending technology that combines advances in high-throughput sequencing with state-of-the-art computer infrastructure to provide an in-depth analysis of the t- and b-cell repertoire, a specific and important part of the immune system. this information is driving the r&d community to support the fights against cancer, auto-immune disease, and much, much more. we're often asked to describe our company culture. it is very easy ... we're a hard working group of top-notch individuals who are passionate about wanting to make a difference in the world. we know our employees are our most valuable asset, and every employee’s contribution is appreciated. open communication and collaboration are always encouraged in every interaction throughout the organization. we have high expectations of ourselves, and
Exchange - NASDAQ
Industry - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Chad Robins
Employees - 831
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.